# A Review of Bryophytes: Enzymatic and Non-Enzymatic Antioxidants as a Key for Their Pharmacological Potential and Green-Biotechnological Application

**Authors:** Stela Ginin, Toncho Dinev, Neli Grozeva, Neli Memdueva, Milena Tzanova

PMC · DOI: 10.3390/antiox15010016 · Antioxidants · 2025-12-22

## TL;DR

This review explores how bryophytes use antioxidant systems to survive stress and their potential for drug discovery and biotechnology.

## Contribution

The paper highlights the pharmacological and biotechnological potential of bryophytes, emphasizing their unique antioxidant enzymes and bioactive compounds.

## Key findings

- Bryophytes have evolved enzymatic and non-enzymatic antioxidant systems to manage oxidative stress.
- They produce bioactive compounds like melatonin and cannabinoids with potential therapeutic applications.
- Bioreactor cultivation and further biochemical studies are needed to fully utilize their therapeutic potential.

## Abstract

Bryophytes, as early land plants, have evolved and developed a wide array of enzymatic and non-enzymatic antioxidant defense mechanisms to cope with oxidative stress. This review explores the intricate biochemical pathways of bryophyte antioxidant defense including their secondary metabolite (SM) systems and protective enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione transferases (GSTs), glutathione peroxidase (GPx), and glutathione reductase (GR). These metabolic components function through species-specific regulatory mechanisms related to expression way. The pharmacological significance of bryophyte-derived compounds is also highlighted, supported by recent discoveries of numerous bioactive molecules, such as melatonin, cannabinoids, and specific chemical marker compounds. Most current biochemical studies on bryophytes focus on their desiccation tolerance and their utility as pollution indicators; however, another aim of this review is to underscore their broader pharmacological promise. Furthermore, this paper explores the biotechnological applications of bryophytes in drug discovery and the need for bioreactor cultivation of the species used. It also emphasizes the need for further investigation into bryophyte biochemistry and enzymology, particularly their unique enzyme systems, to fully unlock their therapeutic potential.

## Linked entities

- **Proteins:** Cat (Catalase), GPX2 (glutathione peroxidase 2), GR (glutathione reductase)
- **Chemicals:** melatonin (PubChem CID 896), cannabinoids (PubChem CID 9852188)

## Full-text entities

- **Genes:** HPGDS (hematopoietic prostaglandin D synthase) [NCBI Gene 27306] {aka GSTS, GSTS1, GSTS1-1, PGD2, PGDS}, CAT (catalase) [NCBI Gene 847], SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}
- **Chemicals:** melatonin (MESH:D008550), cannabinoids (MESH:D002186)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12837394/full.md

## Figures

25 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12837394/full.md

## References

171 references — full list in the complete paper: https://tomesphere.com/paper/PMC12837394/full.md

---
Source: https://tomesphere.com/paper/PMC12837394